Lung cancer remains one of the deadliest cancers due to late
detection. BridgeInDx is building AI-powered tests that combine biomarker panels with patient risk factors, enabling
earlier detection and triage.
Ovarian cancer is often called the “silent killer”
because symptoms are vague and most women are diagnosed at advanced stages. We are working on non-invasive
biomarker-based rapid tests supported by AI algorithms for earlier detection and effective therapy monitoring.
Colorectal cancer is one of the fastest-growing
cancers in India, often undiagnosed until late stages. BridgeInDx is developing stool- and blood-based rapid tests,
combined with AI-driven interpretation, for cost-effective and accessible screening.
We are developing urine-based rapid tests capable of
detecting infections, hematuria, and bladder cancer risk factors. These tests provide quick and accurate results
without invasive procedures, suitable for various healthcare settings and at-home use.
Dogs and cats are family
members, and their health requires attention. BridgeInDx is developing AI-based LFAs for common cancers in canines and
felines. These rapid, non-invasive tests are easy to use in veterinary clinics and at-home care settings, improving
outcomes for pets.
For researchers and
innovators, BridgeInDx simplifies product development. We provide end-to-end consultancy services covering feasibility
studies, prototyping, regulatory strategy, manufacturing scale-up, clinical validation, and market launch, ensuring
scientifically sound and commercially viable products.
We believe in the power of
collaboration. BridgeInDx actively partners with academic institutions, incubators, and healthcare innovators to
develop high-potential diagnostic ideas. We support innovators in bringing their concepts to market, ensuring
accessible and impactful solutions.
